Original Research

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

Beeh KM, Singh D, Di Scala L, Drollmann A

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:503-513

Published Date: 31 July 2012